Join the UNC Program for Precision Medicine in Healthcare (PPMH) for Biomedical Imaging for Precision Diagnosis, Prognosis, and Therapy, a free virtual mini-symposium on Monday November 7, 2022 from 11:00am to 12:00pm ET. At this interactive event, you will engage in discussion with leading Precision Medicine researchers at UNC.
Precision medicine harnesses cutting edge data and technology to provide prediction of disease risk and choice of optimum treatment. Biomedical imaging is an integral part of early diagnosis and individually tailored treatment. The speakers at this mini-symposium will address data-driven approaches to developing personalized treatment strategies.
This dynamic discussion forum will explore the breadth of Precision Health initiatives at UNC and facilitate connections between colleagues with similar research interests. We hope to see you there!
|Mark Shen, PhD
Assistant Professor of Psychiatry & Neuroscience, Carolina Institute for Developmental Disabilities, UNC School of Medicine
Presentation title: Longitudinal neuroimaging to study the brain development of infants with neurodevelopmental disorders
Our lab utilizes longitudinal MRIs to chart the infant brain development of autism, fragile X syndrome, and Angelman syndrome. This presentation will describe: (1) how we conduct MRI scans from 6-24 months of age to detect the earliest brain features of these conditions; and (2) how we leverage both longitudinal neuroimaging in infants, and mechanistic studies in mouse models, to elucidate pathogenic mechanisms and inform potential clinical applications.
|Eran Dayan, PhD
Associate Professor, Department of Radiology
Presentation title: AI-based stratification of progression along the Alzheimer disease continuum
Age-associated neurodegenerative diseases, such as Alzheimer’s disease (AD), are becoming increasingly more prevalent. These diseases are already exerting a significant personal and financial toll on patients and their families, along with a substantial societal economic burden. The projected increase in the prevalence of AD is thus alarming, highlighting the urgent need for advances in research and care. Research I will discuss in my talk tackles the heterogeneity observed along the AD continuum. A better understanding of the heterogeneity of AD may ultimately lead to earlier and more optimal and personalized treatment strategies. Using a combination of deep learning and other model and data-driven approaches our studies aim to reveal the underlying mechanisms that lead to variation in progression rates and develop tools that may eventually be used in clinical settings.
|Andrew Satterlee, PhD
Brain Slice Technology Program Manager, Eshelman Institute for Innovation, Eshelman School of Pharmacy
Presentation title: A living ex vivo platform for functional, personalized brain cancer diagnosis
Functional precision medicine platforms are emerging as promising strategies to improve pre-clinical drug testing and guide clinical decisions. We have developed an organotypic brain slice culture platform and assay which enable rapid engraftment, treatment, and analysis of patient-derived cell lines and fresh, uncultured brain tumor tissue. Measuring direct tumor kill of therapeutics provides additional insight to help understand which drugs will be effective against the residual tumor after resection surgery.
|10:05-10:30||Mark Shen presentation|
|10:30-10:55||Eran Dayan presentation|
|10:55-11:20||Andrew Satterlee presentation|
|11:20-11:55||Q&A and Panel discussion|
Email firstname.lastname@example.org for more information.
Click here to download the event flyer: PPMH mini-symposium poster Nov2022